NASDAQ$PAYS

Paysign Inc · Q4 2019 earnings

Q4 2019 earnings · · Investor relations

Briefing

Reported full year 2019 financial results, with revenue up by 48% to a record $34.7 million and record net income of $7.5 million, an increase of 188%.

Paysign reported full year 2019 financial results, with revenues reaching $34.7 million, a 48% increase compared to 2018. Net income saw a significant increase of 188%, reaching $7.5 million. However, the company's fourth quarter performance contributed to missing the full year revenue guidance.

  • Full year 2019 revenues increased by 48% compared to 2018, reaching $34.7 million.
  • Net income attributable to Paysign, Inc. increased by $4,866,265, or 188%, compared to 2018.
  • Cost of revenues was 44% of total revenues in 2019, an improvement compared to 51% in 2018.
  • The company is focused on maximizing shareholder value and expects continued growth in revenue and net income in 2020.

Headline financials

Total Revenue

$9.77M

Previous: $6.87M+42.2%
EPS (adj)

$0.05

Previous: $0.02+150.0%
Capital Expenditures

$112K

Previous: $39.3K+185.7%
Free Cash Flow

$5.8M

Previous: $7.31M-20.6%
Net Income

$7.45M

Previous: $643K+1060.0%
Operating Income

$1.45M

Previous: $590K+146.5%
Gross Profit

$5.06M

Previous: $3.49M+45.0%
Cash & Equivalents

$45.6M

Previous: $31.7M+43.9%
Total Assets

$53.5M

Previous: $36.2M+48.0%
Stock-Based Comp

$663K

Previous: $611K+8.4%

Revenue & EPS history

Paysign · Revenue · Quarterly

$9.77M

Q4 2019+42.2%vs Q4 2018
Beat estimate in 5 of 8 quarters(63%)
ActualEstimate

Forward guidance

Paysign expects continued growth in both revenue and net income in 2020, with similar gross margins to 2019, driven by plasma and pharma strength, expansion into new industry verticals, and the launch of new products.

Tailwinds

  • Source plasma collection has been deemed critical infrastructure.
  • No anticipated decline in the demand for pharmaceutical patient affordability products.
  • Expansion into new industry verticals.
  • Launch of new products.
  • Company expects to see continued revenue and earnings growth in 2020.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 18 quarterly earnings reports · overlaid with Q4 2019

Historical avgQ4 2019

+16.2%

Avg return

Earnings day

+4.1%

Avg return

5 days after

+7.8%

Avg return

30 days after

44%

27 / 61 earnings

Positive

+900.0%

Q3 2011

Best reaction

-29.6%

Q4 2015

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q4 2025+37.3%-4.3%
Q1 2026-12.6%-12.0%+4.8%
Q3 2025+0.2%-8.8%+0.4%
Q2 2025+13.0%+4.2%+0.6%
Q1 2025+3.0%+22.9%+81.9%
Q4 2024-8.5%-14.5%-8.1%
Q3 2024+10.9%+8.7%-7.9%
Q2 2024-6.7%-14.4%-9.2%
Q1 2024-0.4%+5.4%-7.6%
Q4 2023+20.5%+10.2%+31.9%
Q3 2023+18.1%+21.6%+18.1%
Q2 2023+6.4%+8.6%+16.0%
Q1 2023-1.8%-4.5%-20.7%
Q4 2022+4.2%+7.6%+0.3%
Q3 2022-10.4%+8.9%+16.5%
Q2 2022+7.4%+15.3%+33.5%
Q1 2022-26.2%-20.2%-2.4%
Q4 2021-6.6%-16.6%-21.4%
Q3 2021-9.0%-14.6%-32.8%
Q2 2021-2.4%+5.6%+16.7%
Q1 2021-11.4%-10.8%+0.0%
Q4 2020+11.7%+5.1%+0.8%
Q3 2020-26.8%-20.6%-7.7%
Q2 2020-18.9%-30.5%-45.3%
Q1 2020-5.5%-13.0%-0.4%
Q4 2019+27.3%+82.9%+102.7%
Q3 2019+13.2%+17.1%+3.9%
Q2 2019+2.5%+6.3%+2.7%
Q1 2019-11.7%-6.7%+18.2%
Q4 2018-1.7%-7.5%-1.0%
Q3 2018-0.5%-1.6%-6.3%
Q2 2018+10.1%+2.7%-2.7%
Q1 2018-0.9%+18.8%+23.1%
Q4 2017+19.0%+20.6%+44.3%
Q3 2017+7.9%+19.3%+15.8%
Q2 2017+2.8%+9.4%+0.0%
Q1 2017-8.7%-6.5%-6.5%
Q4 2016+4.7%+0.0%+0.0%
Q3 2016+34.9%+73.7%+73.7%
Q2 2016+0.0%-5.0%-20.0%
Q1 2016-23.2%
Q4 2015-29.6%
Q3 2015-12.0%
Q2 2015+6.3%
Q1 2015+4.3%
Q4 2014+71.2%
Q2 2014-16.7%
Q1 2014+0.0%
Q4 2013+23.4%
Q3 2013-17.9%
Q2 2013-16.6%
Q4 2012-4.3%
Q1 2013-4.3%
Q3 2012+18.5%
Q2 2012+0.0%
Q1 2012+0.0%
Q4 2011+0.0%
Q3 2011+900.0%
Q2 2011+0.0%
Q1 2011+0.0%
Q4 2010+5.0%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro